Baxter

Baxter International, Inc. engages in the provision of a portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies, premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems and pharmacy automation, software, and services. It operates through the following segment: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Baxter reports robust Q4 sales, eyes growth amid operational challenges

Baxter International's Q4 2022 performance reflects strong sales growth and strategic actions to enhance agility and market responsiveness.
While facing challenges such as lower-than-expected earnings and supply chain constraints, the company is focused on cost reduction and operational improvements.
Opportunities lie in R&D investments, cost synergies from the Hillrom integration, and improving backlog and backorders, positioning Baxter for future growth.
Analysts' concerns about operating margins and financial outlook for 2023 highlight the need for continued efficiency measures and strategic planning.

Baxter beats Q1 expectations, plans spin-off for strategic clarity

Baxter's Q1 performance exceeded expectations with sales growth in key segments and adjusted EPS surpassing guidance.
The company is progressing well with its strategic initiatives, including the spin-off of Renal Care and new operating model.
Challenges in legacy businesses and soft hospital spending highlight areas for improvement, while opportunities lie in new product launches and margin enhancement strategies.
Overall, Baxter's focus on innovation, operational efficiency, and market trends positions it for long-term success and growth.

Baxter exceeds Q2 expectations, eyes growth amid strategic actions

Baxter's Q2 2023 performance showcased resilience and adaptability in a dynamic healthcare market, with strategic actions underway to drive operational efficiency and growth.
The company's focus on innovation, safety, and market responsiveness positions it well for future success, despite challenges such as pending divestitures and market uncertainties.
With a strong performance, growth opportunities in key segments, and operational improvements driving margin expansion, Baxter is navigating challenges to capitalize on future growth prospects.

Baxter beats Q3 expectations, eyes growth through strategic initiatives

Baxter's Q3 2023 performance exceeded expectations, with a focus on strategic priorities and the upcoming Kidney Care segment separation.
The company's strengths lie in maintaining market share, operational efficiencies, and maximizing shareholder value through financial analysis.
Challenges include renegotiating contracts, rising energy costs, and achieving organic growth amidst market dynamics.
Opportunities for Baxter include growth through cost improvements, margin programs, and product launches in 2024.

Baxter surpasses Q4 expectations, eyes growth amid inflation challenges

Baxter's Q4 2023 performance exceeded expectations, driven by growth in key segments and strategic initiatives, setting the stage for continued success in 2024.
Despite challenges like inflation and flat growth in certain segments, Baxter's focus on margin improvement, debt management, and growth strategies positions the company for future resilience.
With a strong outlook for 2024, Baxter aims to capitalize on opportunities for growth, margin improvement, and market expansion, supported by a solid financial foundation and strategic priorities.

Baxter surpasses Q1 expectations with focus on innovation and growth

Baxter's Q1 2024 performance exceeded expectations, driven by strong sales growth and focus on innovation, despite challenges in certain segments and geographies.
The company's strategic strengths lie in diverse growth drivers, strong segment margins, and geographic expansion successes, positioning it for continued success.
Addressing challenges in underperforming segments and markets, along with seizing opportunities for improvement and expansion, will be crucial for Baxter's future growth.
With a clear focus on innovation, margin expansion, and shareholder value maximization, Baxter aims to navigate challenges and capitalize on growth prospects for sustained success.

Baxter exceeds Q2 expectations, plans Kidney Care separation for growth

Baxter International's Q2 2024 earnings call highlighted robust performance, strategic initiatives, and a positive outlook for sales growth and earnings per share.
The company's focus on margin improvement, innovation, and operational efficiency positions it well for sustained growth and shareholder value creation.
While facing challenges in certain segments and external factors, Baxter's proactive approach and strong fundamentals offer opportunities for future expansion and success.
Investors can look forward to Baxter's continued commitment to driving growth, expanding margins, and delivering innovative healthcare solutions.

Baxter reports solid Q3 performance amidst challenges and growth opportunities

Baxter International demonstrated resilience in Q3 2024 with sales growth and earnings exceeding expectations despite challenges.
The company's focus on operational efficiency, cost containment, and strategic divestitures positions it well for future growth.
Challenges from Hurricane Helene impact and Kidney Care separation are being addressed with a clear vision for sustained performance.
Opportunities for growth and margin expansion underscore Baxter's commitment to delivering value to shareholders and patients.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. It operates through the following segments: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices, and equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Baxter's (BAX) PrisMax 2 aims to enhance user experience and help in addressing the unique demands of the ICU.

Baxter's (BAX) PrisMax 2 to Simplify Organ Support Therapies

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global leader in acute care, today announced the global launch of PrisMax 2, the latest version of the company's next-generation platform. PrisMax 2 is designed to help simplify delivery of continuous renal replacement therapy (CRRT) and other organ support therapies, while providing hospitals the flexibility to meet the unique demands of the intensive care unit (ICU). The PrisMax 2 system features new solutions within th

Baxter Launches PrisMax 2 System to Advance Critical Care Delivery for Patients and Hospitals

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the UBS Global Healthcare Virtual Conference on Tuesday, May 25, 2021. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 2:00 p.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through June 24, 2021. About Baxter Every day, millions of patients and caregivers rely on

Baxter to Present at the UBS Global Healthcare Virtual Conference

Baxter International Inc.'s (BAX) CEO Joe Almeida on Q1 2021 Results - Earnings Call Transcript

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the first quarter of 2021. “Baxter's medically essential products are fundamental to healthcare, and many have proven pivotal in the fight against COVID-19,” said José (Joe) E. Almeida, chairman, president and chief executive officer. “Our life-sustaining portfolio, broad geographic reach and the ongoing momentum of our business transformation are all key

Baxter Reports First-Quarter 2021 Results

Baxter (BAX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Baxter (BAX) is Poised to Beat Earnings Estimates Again

Baxter's (BAX) first-quarter results are likely to reflect growth in its Acute Therapies business.

Baxter (BAX) to Report Q1 Earnings: What's in the Cards?

Baxter (BAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Baxter International (BAX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, announced today that it has been recognized by the Global Inclusion Index in 11 countries for its inclusion efforts. Baxter Brazil, China, France, Germany, India, Ireland, Italy, Japan, Mexico, Singapore and the UK earned spots on the inaugural Index. The recognition is presented by Seramount (formerly Working Mother Media), the company that produces the U.S.-based Inclusion Index

Baxter Recognized Globally for Inclusion Efforts

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global leader in acute care, today announced it received a new research and development (R&D) grant from the German Federal Ministry of Education and Research (BMBF). With the grant, Baxter will lead an initiative aiming to create a new technology platform enhancing the ability to target selective removal of pathogenic substances during certain extracorporeal (outside the body) blood purification (EBP) therapies. The

Baxter Receives Grant From German Federal Ministry of Education and Research to Lead Extracorporeal Blood Purification Research

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the BofA Securities 2021 Virtual Health Care Conference on Tuesday, May 11, 2021. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 8:45 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through August 11, 2021. About Baxter Every day, millions of patients and careg

Baxter to Present at the BofA Securities 2021 Virtual Health Care Conference

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced that, due to the public health and safety concerns related to the novel coronavirus (COVID-19) pandemic, its Annual Meeting of Stockholders (the 2021 Annual Meeting) will again be held by means of a virtual format only. The 2021 Annual Meeting will be held on Tuesday, May 4, 2021 at 9 a.m., Central Time, as disclosed in Baxter's proxy statement for the meeting. Onli

Baxter To Host Its Annual Meeting Of Stockholders In Virtual Format

DEERFIELD, Ill. & WASHINGTON--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, and the Central Area of The Links, Incorporated, an international not-for-profit comprised of 16,000 women of color, announce a new partnership to bring awareness and resources to the disproportionate challenges affecting Black Americans related to kidney health. Through the partnership, Baxter is committing $600,000 to fund grants to local Links chapters in the organi

Baxter Launches Initiative to Increase Awareness and Education in Black Communities About Kidney Health and Managing Chronic Kidney Disease

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its first-quarter 2021 financial results on Thursday, April 29, 2021 at 7:30 a.m. Central Time. To participate in this conference call please follow this link http://www.directeventreg.com/registration/event/1693119 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter

Baxter to Host First-Quarter 2021 Financial Results Conference Call for Investors

Baxter (BAX) gets FDA approval for its AK 98 Hemodialysis machine that offers a compact, portable and easy-to-use system for dialysis providers.

Baxter (BAX) Receives FDA Nod for AK 98 Hemodialysis Machine

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global innovator in renal care, today announced U.S. Food and Drug Administration (FDA) clearance of its next-generation Artificial Kidney 98 (AK 98) dialysis machine, which is designed to be a portable and easy-to-use system to administer hemodialysis (HD) treatments. AK 98 offers encrypted, two-way connectivity, which enables the system to pull prescriptions directly from the electronic medical record (EMR) for simplifi

Baxter Announces U.S. FDA 510(k) Clearance of AK 98 Hemodialysis Machine

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 10:40 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through September 13, 2021. About Baxter Every day, millions of patients and car

Baxter to Present at Oppenheimer 31st Annual Healthcare Conference

Moderna

Baxter International Inc (NYSE: BAX) has agreed to provide manufacturing services for Moderna Inc's (NASDAQ: MRNA) COVID-19 Vaccine. The agreement includes fill/finish sterile manufacturing services and supply packaging for approximately 60-90 million doses of the Moderna COVID-19 Vaccine in 2021.

Baxter To Offer Fill/Finish Services To Moderna's COVID-19 Vaccine In US

Baxter International Inc. announced Monday an agreement with Moderna Inc. , in which Baxter will provide sterile manufacturing services and supply packaging for 60 million to 90 million doses of Moderna's COVID-19 vaccine. Baxter's stock is little changed in premarket trading, while Moderna shares fell 1.4%.

Baxter to provide sterile manufacturing, packaging for Moderna's COVID-19 vaccine

DEERFIELD, Ill., AND CAMBRIDGE, Mass..--(BUSINESS WIRE)--Baxter BioPharma Solutions and Moderna announce agreement for fill/finish manufacturing of the Moderna COVID-19 Vaccine in the U.S.

Baxter BioPharma Solutions and Moderna Announce Agreement for Fill/Finish Manufacturing of the Moderna COVID-19 Vaccine in the U.S.

Baxter (BAX) reported earnings 30 days ago. What's next for the stock?

Why Is Baxter (BAX) Up 1.1% Since Last Earnings Report?

Alibaba

Equifax

Illumina

Generation Investment Management, the firm co-founded by Al Gore (Trades, Portfolio) and David Blood, disclosed this month that its top four buys during the fourth quarter of 2020 included a new position in Alibaba Group Holding Ltd. (NYSE:BABA) and boosts to its Equifax Inc. (NYSE:EFX), Baxter International Inc. (NYSE:BAX) and Illumina Inc. (NASDAQ:ILMN) holdings.

Top 4 4th-Quarter Buys of Al Gore's Generation Investment Management

Baxter is a moat-worthy healthcare innovation company and ended 2020 with revenue growth. Its shares are still down from a year ago, and I see it as being a solid recovery play.

Why It's Time To Rotate Back To Baxter International

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced it has appointed David S. Wilkes, M.D., dean, University of Virginia School of Medicine, and co-founder and chief scientific officer of biotech start-up ImmuneWorks Inc., to its board of directors. Dr. Wilkes will serve on Baxter's Quality, Compliance and Technology Committee. Additionally, Baxter has appointed Albert P.L. Stroucken, former executive chairman and ch

News for Baxter Stock (BAX)